First patented product to enter clinic within two years
Melbourne, Australia, 04 March 2021.
Cartherics Pty Ltd announced today the grant of a European patent entitled “Genetically modified cells and uses thereof”. The patent covers aspects of Cartherics’ chimeric antigen receptor (CAR) technology, particularly in relation to its CAR directed against the tumour-associated antigen, TAG-72.
This patent is […]